Q-omics provides the consensus-scored CCDC96 profile across patient tissues and cancer cell-line models. CCDC96 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CCDC96 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CCDC96 RNA expression shows 16,489 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, THCA, and KIRP as cancer lineages where CCDC96 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC96 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC96 survival associations across molecular data types. CCDC96 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC96 RNA expression–survival associations across cancer types. High CCDC96 expression shows unfavorable associations in MESO and LGG, but favorable associations in BRCA, UCEC, PAAD and CESC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for CCDC96 RNA expression.
This table summarizes CCDC96 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC96. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC96 shows lower tumor expression in THCA, COAD, LUAD and LUSC and higher tumor expression in LIHC and BRCA. The THCA box plot shows higher CCDC96 RNA expression in normal versus tumor tissue (log2 FC = −1.020, t-test p < 0.001).
This table shows molecular features associated with CCDC96 in patient tissues and cancer cell lines. In patient samples, CCDC96 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC96 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
